Review ArticlesAllogenic Umbilical Cord Tissue for Treatment of Knee OsteoarthritisGupta, Ashim MS, PhD, MBA, DABRM*,†,‡,§,∥; Maffulli, Nicola MD, MS, PhD, FRCP, FRCS (Orth)¶,#,**,†† Author Information *Future Biologics †BioIntegrate, Lawrenceville, GA ‡South Texas Orthopaedic Research Institute (STORI Inc.), Laredo, TX §Veterans in Pain (V.I.P), Valencia, CA ∥General Therapeutics, Cleveland Heights, OH ¶Department of Musculoskeletal Disorders, School of Medicine and Surgery, University of Salerno, Fisciano #San Giovanni di Dio e Ruggi D’Aragona Hospital, “Clinica Orthopedica” Department, Hospital of Salerno, Salerno, Italy **Barts and the London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, Queen Mary University of London, London ††School of Pharmacy and Bioengineering, Keele University School of Medicine, Stoke-on-Trent, Staffordshire, UK Disclosure: The authors declare no conflict of interest. Reprints: Ashim Gupta, MS, PhD, MBA, DABRM, BioIntegrate, 2505 Newpoint Pkwy, Suite 100, Lawrenceville, GA 30043. Sports Medicine and Arthroscopy Review: September 2022 - Volume 30 - Issue 3 - p 162-165 doi: 10.1097/JSA.0000000000000350 Buy Metrics Abstract Interest in use of perinatal allogenic tissues including clinical-grade minimally manipulated umbilical cord tissue-derived allograft formulations to treat knee osteoarthritis (OA) patients is increasing. Limited studies have characterized these formulations and evaluated their safety and efficacy in knee OA patients. We developed such formulation and reported the presence of growth factors, cytokines, hyaluronic acid, and exosomes. We reported that its administration is safe, and resulted in 50% pain reduction and improvement in knee injury and osteoarthritis outcome score (over 10%) and 36-item short form survey (25%). Another study reported no adverse events post injection of similar formulation and statistically significant (P<0.001) improvement in visual analog scale and Western Ontario and McMaster Universities Osteoarthritis Index scores and reduction in medication usage in patients (77.8%). We also summarized the clinical trials registered on ClinicalTrials.gov utilizing umbilical cord tissue for knee OA treatment. In conclusion, available studies are preliminary but pave the way to higher level appropriately powered investigations, and these formulations should be considered as nonoperative alternative to manage knee OA. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.